Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro

被引:103
作者
Ghimire, Tirth R. [1 ,2 ]
Benson, Robert A. [1 ]
Garside, Paul [1 ]
Brewer, James M. [1 ]
机构
[1] Univ Glasgow, Glasgow Biomed Res Ctr 120, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, Scotland
[2] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland
基金
英国生物技术与生命科学研究理事会; 英国惠康基金;
关键词
Alum; Antigen uptake; Processing; Presentation; YAe system; MHC CLASS-II; DENDRITIC CELLS; T-CELLS; HYDROXIDE; DIFFERENTIATION; ADJUVANTS; PEPTIDES; STIMULATION; ACTIVATION; NAIVE;
D O I
10.1016/j.imlet.2012.06.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aluminium adjuvants (alum) have been the only widely approved adjuvants for use in human vaccines since the 1920s, however, the mechanism of action of these adjuvants remains elusive. Due to increasing demand for novel adjuvants, a clearer understanding of the mechanisms that allow these important agents to affect adaptive immune responses will make a significant contribution to the rational design of future vaccines. Using a novel approach to tracking antigen and antigen presentation, we demonstrate that alum induces higher antigen accumulation and increased antigen presentation by dendritic cells (DCs) in vitro. Antigen accumulation was 100-fold higher and antigen presentation 10-fold higher following alum treatment when compared with soluble protein alone. We also observed that alum causes an initial reduction in presentation compared with soluble antigen, but eventually increases the magnitude and duration of antigen presentation. This was associated with reduced protein degradation in DCs following alum treatment. These studies demonstrate the dynamic alterations in antigen processing and presentation induced by alum that underlie enhanced DC function in response to this adjuvant. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 31 条
[1]   The strategy of T cell antigen-presenting cell encounter in antigen-draining lymph nodes revealed by imaging of initial T cell activation [J].
Bajénoff, M ;
Granjeaud, S ;
Guerder, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (05) :715-724
[2]   (How) do aluminium adjuvants work? [J].
Brewer, JM .
IMMUNOLOGY LETTERS, 2006, 102 (01) :10-15
[3]   Real-time manipulation of T cell-dendritic cell interactions in vivo reveals the importance of prolonged contacts for CD4+ T cell activation [J].
Celli, Susanna ;
Lemaitre, Fabrice ;
Bousso, Philippe .
IMMUNITY, 2007, 27 (04) :625-634
[4]   The global impact of vaccines containing aluminium adjuvants [J].
Clements, CJ ;
Griffiths, E .
VACCINE, 2002, 20 :S24-S33
[5]   Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis [J].
Delamarre, Lelia ;
Couture, Rachael ;
Mellman, Ira ;
Trombetta, E. Sergio .
JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 203 (09) :2049-2055
[6]   Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity [J].
Itano, AA ;
McSorley, SJ ;
Reinhardt, RL ;
Ehst, BD ;
Ingulli, E ;
Rudensky, AY ;
Jenkins, MK .
IMMUNITY, 2003, 19 (01) :47-57
[7]   Continued antigen stimulation is not required during CD4+ T cell clonal expansion [J].
Lee, WT ;
Pasos, G ;
Cecchini, L ;
Mittler, JN .
JOURNAL OF IMMUNOLOGY, 2002, 168 (04) :1682-1689
[8]   The duration of antigenic stimulation determines the fate of naive and effector T cells [J].
Lezzi, G ;
Karjalainen, K ;
Lanzavecchia, A .
IMMUNITY, 1998, 8 (01) :89-95
[9]   An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow [J].
Lutz, MB ;
Kukutsch, N ;
Ogilvie, ALJ ;
Rössner, S ;
Koch, F ;
Romani, N ;
Schuler, G .
JOURNAL OF IMMUNOLOGICAL METHODS, 1999, 223 (01) :77-92
[10]  
MANNHALTER JW, 1985, CLIN EXP IMMUNOL, V61, P143